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AMONG the advantages of tacrolimus (Prograf FK506)-based immunosuppression in renal trans-
plant patients has been the ability to withdraw steroids 
completely in the majority of successfully transplanted 
recipients. I- 4 The percentage of patients in whom steroids 
have been discontinued has varied with the length of 
follow-up, but has been as high as 70% or more.2•3 An 
Table 1. Outcome After Steroid Withdrawal 
Withdrawn From Never 
Steroids Withdrawn 
N 289 (76%) 90 (24%) 
Median time to withdrawal (months) 10 
Uving donor 92% 8% 
Cadaveric donor' 75% 25% 
Donor age (y)' 32.9:!: 19.8 38.8: 21.4 
Donors <60 y 79% 21% 
Donors >60 y" 53% 47% 
Tacrolimuslprednisone 77% 22% 
Tacrolimuslprednisonelazathioprine 76% 23% 
Delayed graft function 
... no 81% 19% 
yes 67% 33% 
Acute rejection 
.. no 87% 13% 
65% 35% 
Patient survivalt 
1 y (actual) 99% 91% 
3 Y (actuarial) 98% 80% 
Graft survivalt 
1 y (actual) 98% 77% 
3 Y (actuarial) 94% 50% 
Rejectiont 43% 73% 
Serum creatinine (mgldL) 
1 y" 1.6 :t 0.6 2.3: 1.5 
2 ytt 1.7:0.7 2.3: 1.3 
Cytomegalovirus 15% 23% 
Tacrolimus dose (mglkg per d) 
1 yttt 0.15: 0.11 0.19:!: 0.15 
2 ytttt 0.13 :t 0.08 0.18:!: 0.09 
'p < .02 tp < .0001 mp < .01 
"p < .0001 tt = .001 tmp < .05 
-p = .003 
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important question. however, concerns the outcome in 
these patients, and to date. this issue has not been formally 
investigated. We looked at a large population of well-
studied patients entered into a prospective, randomized 
trial of two tacrolimus-based regimens, with and without 
azathioprine, to answer questions about the short- and 
medium-term safety of steroid withdrawal. 
PATIENTS AND METHODS 
Between August 1. 1991, and December 9, 1993,395 adult patients 
undergoing 397 renal transplantations only were entered into a 
prospective, randomized trial of tacrolimus/prednisone versus ta-
crolimus/azathioprine/prednisone, without induction antilympho-
cyte therapy. The details and overall outcomes of this trial have 
been reported previously"·3.5-7 In this analysis, we excluded the 18 
cases who lost their allograft within 3 weeks after transplantation 
(and who were all still taking steroids at the time of graft loss), and 
studied the 379 remaining cases, focusing on steroid withdrawal. 
Patients were categorized into two groups, those in whom steroids 
were withdrawn and those in whom steroids were never withdrawn. 
A subgroup analysis was performed to examine differences in rates 
of steroid withdrawal. An additional analysis was performed to 
assess the outcomes in the steroid-withdrawn patients and in the 
patients still on steroids. A further analysis was performed to look 
at the timing of steroid withdrawal. 
The idealized timetable for steroid withdrawal began with an 
intraoperative 1000 mg bolus of intravenous methylprednisolone in 
all patients. followed by a taper from 200 to 20 mg/d over 6 days. At 
3 to 4 weeks. the prednisone dose was decreased to 15 mg/d. and by 
2 to 3 months. the dose was tapered by 2.5 mg decrements to 10 
mg/d. Thereafter, the prednisone dose was decreased by 2.5 mg/q4 
to 6 weeks until complete discontinuation. There was considerable 
variability in these timetables; some patients never came off 
prednisone, some came off much later than 6 months after trans-
plantation (in some cases as long as 3 years postoperatively), and a 
few patients came off steroids earlier. 
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Fig 1. Actuarial patient survival. 
This trial was performed before the US Food and Drug Admin-
istration approval of tacrolimus. and was approved. with yearly 
renewals. by the Biomedical Institutional Review Board of the 
University of Pittsburgh. 
RESULTS 
The mean follow-up was 33 ~ 10 months. 
Steroid Withdrawal 
Two hundred eighty nine (76%) patients were taken off 
prednisone. and 90 (24%) never came off prednisone. The 
median time to steroid withdrawal was 10 months (Table 1). 
There were no differences in recipient sex. race, panel 
reactive antibodies. degree of HLA matching or mismatch-
ing, or immunosuppressive regimen between the two 
groups. There was also no difference in donor sex or race. A 
higher percentage of living donor cases (92%) than cadaver 
donor cases (75%) were taken off steroids (P < .03). Donor 
age was also an important factor. A much lower percentage 
of recipients of kidneys from donors over the age of 60 
(53%) were taken off steroids, compared with recipients of 
kidneys from donors under the age of 60 (79%; P < .0004). 
As a corollary. the mean donor age was younger in the 
steroid-withdrawn group (32.9 ~ 19.8 years) than in the 
never-withdrawn group (38.8 ~ 21.4 years; P < .02). 
Patients with delayed graft function (67%) or who experi-
enced acute rejection (65%) were less likely to he withdrawn 
from steroids than patients with immediate function (81%; 
P = .003) or who never had rejection (87%; P < .0001). 
Patient Survival 
In the steroid-withdrawn patients. the I-year actual and 
3-year actuarial patient survival was 99% and 98%. In the 
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Months After Transplantation 
group still on steroids. it was 91 % and 80%, respectively 
(P < .00001) (Fig 1). 
Graft Survival 
In the steroid-withdrawn group. the I-year actual and 
3-year actuarial graft survival was 98% and 94%; in the 
patients never withdrawn from steroids, it was 77% and 
50%, respectively (P < .00001) (Fig. 2). 
Quality of Graft Function 
In the steroid-withdrawn patients. the mean serum creati-
nine at 1 and 2 years was 1.6 ~ 0.6 mgldL. and 1.7 ~ 0.7 
mgldL. In the patients still on steroids, the corresponding 
values were 2.3 :!: 1.5 mgldL (P < .0001) and 2.3 :!: 1.3 
mgldL (P = .001). 
Rejection 
The incidence of rejection in the steroid-withdrawn group was 
43%. In the never-withdrawn group. it was 73% (P < .00001). 
The majority of these rejections occurred in the early post-
transplant period. long before steroids were withdrawn. 
Cytomegalovirus 
The incidence of cytomegaloviral infection in the steroid-
withdrawn group was 15%; in the never-withdrawn group, it 
was 23% (I' = ns). 
Tacrolimus Dosage 
After I and 2 years. the mean tacrolimus dose in the 
steroid-withdrawn patients was 0.15 :!: 0.11 mglkgld and 
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Months After Transplantation Fig. 2. Actuarial graft survival. 
0.13 ::t 0.08 mg/kgld. In the never-withdrawn group, the 
corresponding dosages were 0.19 ::t 0.15 mg/kgld (P < .01) 
and 0.18 ::t 0.09 mg/kg per d (P < .05). 
DISCUSSION 
The primary intent of this analysis was to assess the safety 
of steroid withdrawal in renal transplant recipients receiv-
ing tacrolimus-based immunosuppression. Viewed strictly 
from that perspective, steroid withdrawal was associated 
with excellent patient and graft survival and stable renal 
function. The incidence of rejection, while high, was not 
inconsistent with our previous reports of this study!·3 and 
has parenthetically stimulated other subsequent studies to 
attempt to reduce the incidence of acute rejection in our 
transplant population.s The poor outcomes in the patients 
never taken off steroids were somewhat unexpected. An 
argument can be made that these differences in outcomes 
between steroid-withdrawn and never-withdrawn patients is 
merely a reflection of differences between a group of 
patients who did well and a group of patients with ongoing 
problems after transplantation. An alternative, but not 
necessarily conflicting, argument is that steroid withdrawal 
facilitated the mutual acceptance between donor and recip-
ient. consistent with the role of chimerism in long-term 
graft survivaI.9 - 12 Unfortunately, this cohort of patients was 
not routinely analyzed for chimerism. 
Ultimately. of course, a rigorous analysis of the effect of 
steroid withdrawal will have to be made with a prospective. 
randomized trial. While the patients entered into this trial 
were randomly assigned to double or triple therapy, steroid 
withdrawal was not randomized, and, indeed, was the 
theoretic goal in all patients. 
The main lesson from this analysis is that steroid withdrawal 
in renal transplant patients receiving tacrolimus-based immu-
nosuppression is possible most of the time and seems to be 
reasonably safe. in terms of short- and medium-term patient 
and graft survival and stability of renal function. More fol-
low-up will be required to assess the longer-term outcome. 
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